Drug Profile
Research programme: osteoporosis therapeutics - Takeda
Alternative Names: TAK-075Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Takeda
- Class
- Mechanism of Action Calcium-sensing receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in Japan (PO)
- 31 Mar 2011 Preclinical trials in Osteoporosis in Japan (PO)